AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01178112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin MTD
Description: Maximum tolerated dose found in MTD Dose Escalation Group
Study NCT01178112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PK Testing
Description: Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
Study NCT04106947 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires
Study NCT02996617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF regimen
Description: Patients weren't preventive use of rhG-CSF.If their WBC≤1×10\^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10\^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
Study NCT02996617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF regimen
Description: Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
Study NCT03304210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Abraxane
Description: Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.
Study NCT04182984 — intervention group
Intervention type: DRUG
Intervention: Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)
Description: Treatment regimens are determined according to the physician's judgment and preferences of the patients.
Study NCT02624349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadravalent human papillomavirus vaccine
Description: Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
Study NCT01251692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
Study NCT02600273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual brand cigarettes
Description: Usual brand cigarettes
Study NCT02600273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower nicotine content cigarettes
Description: SPECTRUM research cigarettes
Study NCT02600273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes 1
Description: Electronic cigarette with 0 g/mL e-liquid
Study NCT02600273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes 2
Description: Electronic cigarette with 18 g/mL e-liquid
Study NCT02959554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
Study NCT02959554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
Study NCT02959554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
Study NCT02136797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMVpp65 Specific T-cells
Study NCT01810328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traumatized population
Description: In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
Study NCT01810328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Volunteers
Description: The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
Study NCT02585752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Expiratory pressure modulation
Study NCT03310372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrafractionated brain irradiation
Description: 0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)
Study NCT03310372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
Study NCT00841945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: RITUXIMAB 375 MG/M² IV DAY 1 or each course
Study NCT00841945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: RITUXIMAB 375 MG/M² IV DAY 1 or each course
Study NCT00841945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: doxorubicin 50 mg / m² iv day 1 of each course
Study NCT00841945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: doxorubicin 50 mg / m² iv day 1 of each course
Study NCT00841945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: VINCRISTINE 1?4 MG/M² IV ON DAY 1
Study NCT00841945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: VINCRISTINE 1?4 MG/M² IV ON DAY 1
Study NCT00841945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone 40 mg/m² DAy 1 to day 5
Study NCT00841945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone 40 mg/m² DAy 1 to day 5
Study NCT00841945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy : total dose = 40 GY (5 fractions by week)
Study NCT04221308 — intervention group
Intervention type: DEVICE
Intervention: Single port laparoscopic systems
Description: The first assistant handles the scope from the patient's right side. The second assistant, who is positioned between the legs of the patient, inserts a uterine manipulator (Rumi System; Cooper Surgical, CT). At the beginning of the surgery, a 1.5 to 2.5 cm vertical incision is made within the umbilicus using the open Hasson approach. After the bottom retractor ring of the wound retractor component of the Octo-Port is inverted (DalimSurgNet, Seoul, Korea), it is inserted through the incision deep in the peritoneum. Carbon dioxide is insufflated through the gas valve of the Octo-Port to maintain intra-abdominal pressure at 10 to 12 mm Hg. Through the 10 mm channels of the Octo-Port, a 10 mm, 30° rigid laparoscope is introduced. Rigid laparoscopic instruments are introduced through the 5 mm channels of the Octo-Port. The utero-ovarian ligament or infundibulopelvic ligament, uterine vessels, and uterine ligaments are transected by using the 5 mm LigaSure vessel sealer device
Study NCT01179659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Description: Single dose crossover BE study
Study NCT01179659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Description: Single dose crossover BE study
Study NCT03965481 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dynamic Enhanced CT
Description: Undergo standard CECT
Study NCT03965481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI scan
Study NCT03965481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI scan
Study NCT00647374 — intervention group
Intervention type: OTHER
Intervention: this is an observational study
Study NCT01375777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT01375777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day
Study NCT01375777 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT05399667 — intervention group
Intervention type: OTHER
Intervention: Early stimulation
Description: Preterm born children submitted to skin-to skin care (kangaroo care ) plus massage therapy by their mothers. This group received tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
Study NCT05399667 — intervention group
Intervention type: OTHER
Intervention: Conventional care
Description: Preterm born children submitted to skin-to skin care by their mothers (kangaroo care), associated to standard care according to the routine care in the Neonatal Intensive Care Unit (NICU).
Study NCT04888208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
Study NCT03746886 — intervention group
Intervention type: OTHER
Intervention: Breast-milk
Description: A single breast-milk sample will be collected from 20 women. Milk samples will be pooled for analysis.
Study NCT01749033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 Classic
Description: Active Comparator: Group 1 classic~Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual.
Study NCT01749033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 pre-inflated
Description: Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer.
Study NCT01749033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3 ELL-PIC
Description: Group 3 (ELL-PIC): Using the ELL-PIC technique
Study NCT03294447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall Prevention by the Occupational Therapist
Description: The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
Study NCT02917109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LearningRx cognitive training
Description: A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
Study NCT00745927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CO2 insufflations
Description: CO2 insufflations during whole procedure of colonoscopy
Study NCT04461522 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound-guided drug injection
Description: The injection drugs were glucocorticoids and anesthetic drugs (1ml+2% lidocaine hydrochloride 0.5ml+0.9% sodium chloride 0.5ml), and the injection sites were subacromion deltoid bursa/coracoid bursa/biceps longhead tenosynosheath/glenohumeral joint bursa, etc.
Study NCT02715765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
Study NCT02715765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Random Noise Stimulation
Description: Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
Study NCT02715765 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Sham Stimulation
Description: Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
Study NCT02356016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WB-EMS Intervention
Description: Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
Study NCT02356016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WB-EMS-Intervention and dietary supplementation
Description: Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
Study NCT02356016 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control (dietary counseling)
Description: Monthly dietary counseling only
Study NCT01990443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab IV
Description: Reslizumab 220-mg intravenous (IV)
Study NCT01990443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab SC
Description: Reslizumab 220 mg administered subcutaneous (SC)
Study NCT02060890 — intervention group
Intervention type: OTHER
Intervention: specialized tumor board recommendation
Description: feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
Study NCT02578394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra 100mg and Placebo Depo-Medrone
Description: Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.
Study NCT02578394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medrone 120mg and Placebo (Anakinra)
Description: Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
Study NCT03086447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: Senofilcon C Toric
Study NCT03086447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens
Description: Air Optix for Astigmatism
Study NCT01213017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: certolizumab pegol
Description: 400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
Study NCT04211103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
Study NCT00765908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty balloon
Description: 90 second balloon inflation x 2
Study NCT00765908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty balloon
Description: 30 seconds or less balloon inflations x 2
Study NCT03216837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation
Description: The primary intervention will be cathodal (inhibitory) tDCS over the contralesional M1. Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle. The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp. tDCS will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
Study NCT03216837 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle.The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp and then ramp down over 30 seconds to 0 milliamps. Sham will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
Study NCT02200822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta blockers
Study NCT03701490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone subcutaneous
Description: 25 mg/twice a day.
Study NCT03701490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Vaginal Product
Description: 200 mg three times a day.
Study NCT01359072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self administered coping intervention
Description: The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
Study NCT03405909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: contrast enhanced ultrasound (CEUS)
Description: CEUS with SonoVue following standardized protocol
Study NCT03405909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: CE-MRI following standardized protocol
Study NCT03405909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histology
Description: diagnostic liver biopsy
Study NCT02556931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -6 through -2: 30 mg/m\^2 IV daily
Study NCT02556931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily